---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-22-005894"
form_type: "8-K"
ticker: "AIM"
cik: "0000946644"
company_name: "AIM ImmunoTech Inc."
filed_at: "2022-03-03T23:59:59+00:00"
generated_at: "2026-06-27T02:15:04.197679+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# AIM ImmunoTech appoints Robert Dickey IV as CFO; Lintal transitions to consultant

## Summary
- Robert Dickey IV becomes CFO effective April 4, 2022, replacing Ellen Lintal who moves to consultant role.
- Dickey compensated $375/hour under a one-year consulting agreement with his firm Foresite Advisors.
- Dickey brings 25+ years of life science CFO and investment banking experience, including 18 years at Lehman Brothers.
- He previously served as senior vice president of AIM from 2008 to 2013.
- Press release issued March 3, 2022; contract terminable on 60-day notice (non-cause) or 30-day (cause).

## SEC filing metadata
- accession: 0001493152-22-005894
- form_type: 8-K
- ticker: AIM
- cik: 0000946644
- company_name: AIM ImmunoTech Inc.
- filed_at: 2022-03-03T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 1.01, 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/946644/000149315222005894/0001493152-22-005894-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/946644/000149315222005894/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-22-005894
- JSON: https://secwatch.observer/filing/0001493152-22-005894.json
- Plain text: https://secwatch.observer/filing/0001493152-22-005894.txt

## Key facts
- Executive change
  Ellen Lintal departed as Chief Financial Officer at AIM ImmunoTech Inc..
  - Action: stepped down
  - Role: Chief Financial Officer
  source text: On March 1, 2022, the Company entered into a consulting agreement with Ellen Lintal, who will step down as the Company’s Chief Financial Officer on April 4, 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/946644/000149315222005894/0001493152-22-005894-index.htm
- Executive change
  Robert Dickey IV was appointed as Chief Financial Officer at AIM ImmunoTech Inc..
  - Action: appointed
  - Role: Chief Financial Officer
  source text: On March 1, 2022, after review and approval by the Board of Directors, the Company entered into a consulting agreement with Foresite Advisors, LLC, a company wholly-owned by Robert Dickey IV, pursuant to which Mr. Dickey will serve as the Company’s new Chief Financial Officer effective April 4, 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/946644/000149315222005894/0001493152-22-005894-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.